Everest Medicines Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 1952.HK | 1877.HK | BMRN | INSM | 1177.HK | ZLAB | |
|---|---|---|---|---|---|---|
| Market cap | 12.75B | 17.65B | 10.81B | 20.68B | 95.24B | 2.71B |
| P/E (TTM) | — | — | 150.9 | — | 35.7 | — |
| Forward P/E | 26.5 | 86.2 | 8.7 | 113.5 | 17.0 | -11.5 |
| Price/book | 1.7 | 2.5 | 1.7 | 27.3 | 2.5 | 4.5 |
| Dividend yield | — | — | — | — | 2.59% | — |
| 1-year change | −36.35% | −37.10% | +5.75% | −40.36% | −25.00% | −13.78% |
| Today | +6.69% | +3.74% | −1.10% | −1.03% | −0.93% | −3.65% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1952.HK news ›Everest Medicines Recruits Moderna Cancer Vaccine Veterans to Accelerate U.S. mRNA Clinical Pipeline
Hong Kong-listed innovative drug company Everest Medicines announced on October 9 the appointment of two former Moderna scientists, Dr. Lakshmi Srinivasan and Dr. Brandon Coder, as Senior Vice President and Head of Translational Medicine,…
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
finance.biggo.com1
-
tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.